Gut microbial-host metabolic interactions following bariatric surgery
File(s)
Author(s)
Phetcharaburanin, Jutarop
Type
Thesis
Abstract
Obesity has emerged as one of the major global socioeconomic healthcare burdens at
present. Bariatric surgery, especially Roux-en-Y gastric bypass (RYGB) has been largely
utilised to treat individual suffering from morbid obesity. In the current study, a
hyperinsulinemic obese Zucker rat model was employed to study two different weight loss
approaches, RYGB and caloric restriction. To understand the host metabolic-microbial
cross-talk, the two major analytical platforms including nuclear magnetic resonance (NMR)
spectroscopy and 16S rRNA gene Illumina MiSeq sequencing were used in companion with
multivariate statistical analysis to extract useful information from data with high complexity.
The aim of this study was to 1) characterise the genotype-associated metabolic and
microbial fingerprints; 2) investigate the dynamic changes in biofluids from RYGB-treated or
caloric restriction-treated obese Zucker rats; 3) investigate genotype-related, RYGBinduced or caloric restriction-induced metabolic profiles and microbial shifts of the luminal
contents; and 4) investigate the statistical correlation between metabolites and gut
microbiota following either of the weight loss treatment.
Metabolic observations of portal vein and peripheral blood plasma profiles in both obese
and lean Zucker rats indicated the phenotype-independent absorption of short-chain fatty
acids (SCFAs), choline and trimethylamine (TMA). However, phenotype-specific urinary
host-microbial co-metabolites were revealed, suggesting distinct gut microbial metabolic
activities in lean and obese Zucker rats. Furthermore, metabolic alterations induced by the
RYGB surgery included the enhanced production of neuroactive metabolites, branchedchain amino acid (BCAA) catabolism, aromatic amino acid metabolism with lower
lipogenesis and SCFA production. Even though caloric restriction demonstrated some
health benefit-related biochemical and microbial markers, its effectiveness as a resolution
for metabolic syndrome, especially type-2 diabetes mellitus has not been observed in this
study in spite of the significant weight reduction.
present. Bariatric surgery, especially Roux-en-Y gastric bypass (RYGB) has been largely
utilised to treat individual suffering from morbid obesity. In the current study, a
hyperinsulinemic obese Zucker rat model was employed to study two different weight loss
approaches, RYGB and caloric restriction. To understand the host metabolic-microbial
cross-talk, the two major analytical platforms including nuclear magnetic resonance (NMR)
spectroscopy and 16S rRNA gene Illumina MiSeq sequencing were used in companion with
multivariate statistical analysis to extract useful information from data with high complexity.
The aim of this study was to 1) characterise the genotype-associated metabolic and
microbial fingerprints; 2) investigate the dynamic changes in biofluids from RYGB-treated or
caloric restriction-treated obese Zucker rats; 3) investigate genotype-related, RYGBinduced or caloric restriction-induced metabolic profiles and microbial shifts of the luminal
contents; and 4) investigate the statistical correlation between metabolites and gut
microbiota following either of the weight loss treatment.
Metabolic observations of portal vein and peripheral blood plasma profiles in both obese
and lean Zucker rats indicated the phenotype-independent absorption of short-chain fatty
acids (SCFAs), choline and trimethylamine (TMA). However, phenotype-specific urinary
host-microbial co-metabolites were revealed, suggesting distinct gut microbial metabolic
activities in lean and obese Zucker rats. Furthermore, metabolic alterations induced by the
RYGB surgery included the enhanced production of neuroactive metabolites, branchedchain amino acid (BCAA) catabolism, aromatic amino acid metabolism with lower
lipogenesis and SCFA production. Even though caloric restriction demonstrated some
health benefit-related biochemical and microbial markers, its effectiveness as a resolution
for metabolic syndrome, especially type-2 diabetes mellitus has not been observed in this
study in spite of the significant weight reduction.
Version
Open Access
Date Issued
2018-04
Date Awarded
2018-07
Copyright Statement
Attribution NoDerivatives 4.0 International Licence (CC BY-ND)
Advisor
Li, Jia
Marchesi, Julian
Nicholson, Jeremy
Sponsor
Imperial College London
Mahawitthayalai Khon Kaen
Publisher Department
Department of Surgery & Cancer
Publisher Institution
Imperial College London
Qualification Level
Doctoral
Qualification Name
Doctor of Philosophy (PhD)